...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes, obesity & metabolism >The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome
【24h】

The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome

机译：依泽替米贝/辛伐他汀联合使用强化降脂治疗策略在有或没有代谢综合征的糖尿病患者中的疗效和安全性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims: The objective was to assess the consistency of effect of switching to ezetimibe/simvastatin 10/20mg versus doubling the baseline statin dose (to simvastatin 40mg or atorvastatin 20mg) or switching to rosuvastatin 10mg across subgroups of subjects with (n=617) and without (n=191) metabolic syndrome (MetS). Methods: This was a post hoc analysis of a randomized, double-blind, 6-week study of adults 18-79years with cardiovascular disease and diabetes mellitus with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160mg/dl. The percent change in LDL-C and other lipids was estimated within each subgroup separately. Safety and tolerability were assessed. Results: In subjects with MetS, percent changes in LDL-C and other lipids were greater with ezetimibe/simvastatin versus doubling baseline statin or numerically greater versus switching to rosuvastatin, except high-density lipoprotein cholesterol and apolipoprotein (Apo) AI (mean percent changes in LDL-C were: -22.49% ezetimibe/simvastatin, -9.64% doubled baseline statin and -19.20% rosuvastatin). In subjects without MetS, percent changes in LDL-C, total cholesterol and Apo B were greater with ezetimibe/simvastatin versus doubling baseline statin or numerically greater versus switching to rosuvastatin (mean percent changes in LDL-C were: -25.14% ezetimibe/simvastatin, -4.75% doubled baseline statin and -19.75% rosuvastatin). Safety profiles were generally similar. Conclusion: These results showed that switching to ezetimibe/simvastatin 10/20mg was more effective at reducing LDL-C, total cholesterol and Apo B versus doubling the baseline statin dose to simvastatin 40mg or atorvastatin 20mg or switching to rosuvastatin 10mg regardless of MetS status. These results were generally similar to those of the full cohort.
机译：目的：目的是评估在（n = 617）和（n = 617）的受试者亚组中，转用依泽替米贝/辛伐他汀10 / 20mg与基线他汀类药物剂量加倍（辛伐他汀40mg或阿托伐他汀20mg）或瑞舒伐他汀10mg效果的一致性。没有（n = 191）代谢综合症（MetS）。方法：这是一项对18-79岁患有心血管疾病和低密度脂蛋白胆固醇（LDL-C）≥70和≤160mg/ dl的糖尿病的成年人进行的随机，双盲，为期6周研究的事后分析。在每个亚组中分别估计了LDL-C和其他脂质的变化百分比。评估安全性和耐受性。结果：在患有MetS的受试者中，依泽替米贝/辛伐他汀与基线他汀类药物加倍相比，LDL-C和其他脂质的变化百分比更大，而与切换为瑞舒伐他汀相比在数值上更大，除了高密度脂蛋白胆固醇和载脂蛋白（Apo）AI（平均变化百分比）在LDL-C中的受试者为：-22.49％的依泽替米贝/辛伐他汀，-9.64％的基线他汀类药物加倍和-19.20％的瑞舒伐他汀）。在没有MetS的受试者中，依泽替米贝/辛伐他汀与基线他汀类药物加倍相比，LDL-C，总胆固醇和Apo B的变化百分比更大，而与切换为瑞舒伐他汀相比则在数值上更大（LDL-C的平均百分比变化为：-25.14％依泽替米贝/辛伐他汀，-4.75％的他汀类他汀和-19.75％的瑞舒伐他汀加倍。安全概况通常相似。结论：这些结果表明，与MetS状态无关，将基线他汀类药物剂量增加一倍至辛伐他汀40mg或阿托伐他汀20mg或改为瑞舒伐他汀10mg，改用ezetimibe / simvastatin 10 / 20mg可以更有效地降低LDL-C，总胆固醇和Apo B.这些结果通常与整个队列的结果相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号